
Oncology NEWS International
- Oncology NEWS International Vol 17 No 2
- Volume 17
- Issue 2
Kosan opens TIME-1 pivotal trial of tanespimycin in myeloma
Kosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment
HAYWARD, CaliforniaKosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment. Approximately 470 patients with first-relapse disease will be randomized to treatment with bortezomib (Velcade) plus tanespimycin or bortezomib alone.
Articles in this issue
about 18 years ago
NLST article not balanced, critic of screening trial assertsabout 18 years ago
M.D. Anderson and AstraZeneca form neuropathic pain allianceabout 18 years ago
Good nilotinib responses in imatinib-resistant AP-CMLabout 18 years ago
Virus linked to Merkel cell carcinomaabout 18 years ago
Benefit of adjuvant RT/CT for pancreatic ca affirmedabout 18 years ago
Recurrence Score helps select node+ pts for chemoabout 18 years ago
For resectable liver mets: Preop chemotherapy or not?about 18 years ago
Plerixafor boosts stem cell mobilization in myeloma ptsabout 18 years ago
MRI shows second-hand smoke damageabout 18 years ago
Assay has high sensitivity for hard-to-detect SLN metsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.




































